drugset / Trial / NCT00676910
A Research Study of JNJ-26854165 to Determine the Safety and Dose in Patients With Advanced Stage or Refractory Solid Tumors.
Non-randomizedSingle-groupOpen-labelTreatment
Summary
The purpose of this study is to assess the safety of JNJ-26854165 (a new drug in development for cancer) in patients with advanced or refractory solid tumors on the maximum dose tolerated by these patients.
Timeline
- Start
- 2006-11
- Primary completion
- —
- Completion
- 2010-02
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | SERDEMETAN | Small molecule | 4 mg | Oral |